)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Avacta Group
Avacta Group (AVCT) investor relations material
Avacta Group H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
Achieved clinical validation for the pre|CISION® platform, with AVA6103 showing proof of mechanism and favorable safety in Phase 1a trials for solid tumors, outperforming marketed ADCs in preclinical studies.
Advanced AVA6207 dual payload program and AVA6000 (faridoxorubicin), with updated efficacy and pharmacology data presented at major oncology conferences.
Strengthened leadership with new Board appointments and raised approximately £19 million through equity placements and subscriptions to support R&D and operational runway.
Financial highlights
Revenue from continuing operations was £0.06 million for H1 2026, unchanged from H1 2025.
Operating loss from continuing operations decreased to £13.91 million (H1 2025: £14.18 million).
Loss after tax from continuing operations was £19.02 million (H1 2025: £16.13 million).
Cash and cash equivalents at 30 June 2026 were £20.27 million (31 December 2025: £16.86 million), with £10.59 million as of 31 August 2026.
Net assets at 30 June 2026 were £3.77 million (30 June 2025: £0.14 million).
Outlook and guidance
First efficacy data from the FOCUS-01 trial with AVA6103 expected in H1 2027.
Dual payload program (AVA6207) payload selection and clinical candidate data to be presented in Q4 2026.
Updated AVA6000 clinical data to be presented at ESMO Congress in October 2026.
Current cash runway extends into early Q1 2027, with additional capital raise planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Avacta Group
- pre|CISION® PDCs deliver potent, tumor-selective therapy with superior safety and efficacy.AVCT
Corporate presentation - Clinical progress, new leadership, and financial strategy were central themes at the AGM.AVCTAGM 2025
- Strong R&D advances and successful fundraising set up key clinical milestones for late 2026.AVCTAGM 2026 presentation
- Advanced oncology pipeline, strong R&D spend, and cash runway into 2027 with key data ahead.AVCTH2 2025
- Tumor-selective drug delivery platform shows strong early efficacy and safety, with major milestones ahead.AVCTCorporate presentation
- Clinical pipeline advances, cash runway extends to Q1 2026, and industry interest grows.AVCTH1 2025
- Diagnostics turned EBITDA positive as AVA6000 advanced and Diagnostics divestment progressed.AVCTH1 2024
- Focused on AVA6000's clinical progress, board evolution, and strategic funding for 2024 milestones.AVCTAGM 2024
- Advanced oncology pipeline, strong clinical data, and cash runway into Q1 2026; more funding needed.AVCTH2 2024
Avacta Group
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage